130 related articles for article (PubMed ID: 30659513)
21. Patients' Preferences for Information About the Benefits and Risks of Second-Line Palliative Chemotherapy and Their Oncologist's Awareness of These Preferences.
Oostendorp LJ; Ottevanger PB; van de Wouw AJ; Honkoop AH; Los M; van der Graaf WT; Stalmeier PF
J Cancer Educ; 2016 Sep; 31(3):443-8. PubMed ID: 25985960
[TBL] [Abstract][Full Text] [Related]
22. Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects.
Le H; Ryan K; Wahlstrom SK; Maculaitis MC; Will O; Mulvihill E; LeBlanc TW
Patient Prefer Adherence; 2021; 15():99-110. PubMed ID: 33519195
[TBL] [Abstract][Full Text] [Related]
23. A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.
Wagner MJ; Amodu LI; Duh MS; Korves C; Solleza F; Manson SC; Diaz J; Neary MP; Demetri GD
BMC Cancer; 2015 Mar; 15():175. PubMed ID: 25885530
[TBL] [Abstract][Full Text] [Related]
24. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
[TBL] [Abstract][Full Text] [Related]
25. Importance of patient reported and clinical outcomes for patients with locally advanced rectal cancer and their treating physicians. Do clinicians know what patients want?
van der Valk MJM; van der Sande ME; Toebes RE; Breukink SO; Bröker MEE; Doornebosch PG; Maliko N; Neijenhuis PA; Marinelli AWKS; Peters FP; Peeters KCMJ; Beets GL; Marang-van de Mheen PJ; Hilling DE
Eur J Surg Oncol; 2020 Sep; 46(9):1634-1641. PubMed ID: 32336626
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Younger E; Litière S; Le Cesne A; Mir O; Gelderblom H; Italiano A; Marreaud S; Jones RL; Gronchi A; van der Graaf WTA
Oncologist; 2018 Oct; 23(10):1250-1259. PubMed ID: 29650688
[TBL] [Abstract][Full Text] [Related]
27. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Lindner LH; Litière S; Sleijfer S; Benson C; Italiano A; Kasper B; Messiou C; Gelderblom H; Wardelmann E; Le Cesne A; Blay JY; Marreaud S; Hindi N; Desar IME; Gronchi A; van der Graaf WTA
Int J Cancer; 2018 Jun; 142(12):2610-2620. PubMed ID: 29383713
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
Samuels BL; Chawla S; Patel S; von Mehren M; Hamm J; Kaiser PE; Schuetze S; Li J; Aymes A; Demetri GD
Ann Oncol; 2013 Jun; 24(6):1703-9. PubMed ID: 23385197
[TBL] [Abstract][Full Text] [Related]
31. Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.
Reed D; Altiok S
Cancer Control; 2011 Jul; 18(3):188-95. PubMed ID: 21666581
[TBL] [Abstract][Full Text] [Related]
32. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.
Uemura H; Matsubara N; Kimura G; Yamaguchi A; Ledesma DA; DiBonaventura M; Mohamed AF; Basurto E; McKinnon I; Wang E; Concialdi K; Narimatsu A; Aitoku Y
BMC Urol; 2016 Nov; 16(1):63. PubMed ID: 27814714
[TBL] [Abstract][Full Text] [Related]
33. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
34. Patient Preferences Concerning Alternative Treatments for Neuroendocrine Tumors: Results of the "PIANO-Study".
Mühlbacher AC; Juhnke C
Int J Technol Assess Health Care; 2019 Jan; 35(3):243-251. PubMed ID: 31044688
[TBL] [Abstract][Full Text] [Related]
35. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
González JM; Doan J; Gebben DJ; Boeri M; Fishman M
Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
[TBL] [Abstract][Full Text] [Related]
36. Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study.
Kim HJ; Kim Y; Lee SJ; Lee J; Park SH
J Gynecol Oncol; 2018 Jan; 29(1):e3. PubMed ID: 29185261
[TBL] [Abstract][Full Text] [Related]
37. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
38. Physicians' preferences for bone metastases drug therapy in the United States.
Arellano J; Hauber AB; Mohamed AF; Gonzalez JM; Collins H; Hechmati G; Gatta F; Qian Y
Value Health; 2015 Jan; 18(1):78-83. PubMed ID: 25595237
[TBL] [Abstract][Full Text] [Related]
39. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
40. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
